Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Procedure: Sentinel Lymph Node Biopsy (SLNB)Biological: Tumor-draining lymph node-derived lymphocyte (LNL)Biological: Interleukin-2
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 196
- Registration Number
- NCT05981014
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 116
- Registration Number
- NCT05978648
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1736
- Registration Number
- NCT05901428
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT05900206
- Locations
- 🇸🇪
Stockholm Southern Hospital, Stockholm, Sweden
🇸🇪Skåne University Hospital, Malmö, Sweden
🇸🇪Sankt Gorans Hospital, Stockholm, Sweden
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05887726
- Locations
- 🇨🇳
Xing Xiaojing, Shenyang, Liaoning, China
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Conditions
- HER2 Positive Early Breast Cancer
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1406
- Registration Number
- NCT05883852
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-01-12
- Target Recruit Count
- 26
- Registration Number
- NCT05681728
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- Conditions
- Peripheral T-cell Lymphoma Targeted Therapy
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 204
- Registration Number
- NCT05656079
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Breast NeoplasmHER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorBreast CancerBreast TumorsHormone Receptor Negative TumorTriple-Negative Breast Cancer (TNBC)Locally Advanced Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.